Galindo, Rodolfo J. http://orcid.org/0000-0002-9295-3225
Dhatariya, Ketan
Gomez-Peralta, Fernando
Umpierrez, Guillermo E.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK123384, P30DK111024)
Article History
Accepted: 14 February 2022
First Online: 4 May 2022
Declarations
:
: R. J. G. received research support to Emory University for investigator-initiated studies from Novo Nordisk, Dexcom, and Eli Lilly and consulting fees from Abbott Diabetes Care, Sanofi, Valeritas, Eli Lilly, Novo Nordisk, and Weight Watchers, outside of this work. GEU has also received unrestricted research support for research studies (to Emory University) from Merck, Novo Nordisk, Dexcom Inc., and Sanofi. K. D. Has received speaker fees, travel or taken part in advisory boards for AstraZeneca, Sanofi Diabetes, Boehringer Ingelheim, Lilly or Novo Nordisk. F. G. P. has taken part in advisory panels for Sanofi and Novo Nordisk; has received research support from Sanofi, Novo Nordisk, Boehringer Ingelheim Pharmaceuticals, and Lilly; and has acted as a speaker for Sanofi, Novo Nordisk, Boehringer Ingelheim Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, and Lilly.
: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the US government.
Free to read: This content has been made available to all.